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Abstract
Objectives The current understanding of cerebral waste clearance (CWC) involves cerebrospinal fluid (CSF) participation but
lacks convincing evidence for the direct participation of the parenchymal vascular system. The objective of this study was to
evaluate the role of the parenchymal vascular system in CSF tracer clearance in rats.
Methods We used superparamagnetic iron oxide–enhanced susceptibility-weighted imaging (SPIO-SWI) and quantitative susceptibility mapping (QSM) methods to simultaneously study 7 T MRI signal changes in parenchymal veins, arteries, and their
corresponding para-vascular spaces in 26 rats, following intra-cisterna magna (ICM) infusion of different CSF tracers (FeREX,
Ferumoxytol, Fe-Dextran) to determine the amount of tracer in the artery and vein quantitatively.
Results We observed that the parenchymal venous system participated in CSF tracer clearance following ICM infusion of
different MRI tracers with different concentrations of iron. Parenchymal venous participation was more obvious when 75 μg
iron was injected. In the parenchymal veins, the relative mean (± SE) value of the susceptibility increased by 13.5 (± 1.0)% at
15 min post-tracer infusion (p < 0.01), and 33.6 (± 6.7)% at 45 min post-tracer infusion (p = 0.01), compared to baseline. In
contrast to the parenchymal veins, a negligible amount of CSF tracer entered the parenchymal arteries: 1.3 (± 2.6)% at 15 min
post-tracer infusion (p = 0.6), and 12 (± 19)% at 45 min post-tracer infusion (p = 0.5), compared to baseline.
Conclusions MRI tracers can enter the parenchymal vascular system and more MRI tracers were observed in the cerebral venous
than arterial vessels, suggesting the direct participation of parenchymal vascular system in CWC.
Key points
• MRI results revealed that the parenchymal venous system directly participates in cerebrospinal fluid tracer clearance following
ICM infusion of MRI tracer.
• Different sizes of MRI tracers can enter the parenchymal venous system.
Keywords Rats . Glymphatic system . Cerebral veins . Contrast media . Magnetic resonance imaging
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Introduction
Impaired cerebral waste clearance (CWC) has been associated
with a broad range of both physiological and pathophysiological neurologic conditions in animal studies, making it a
focus-of-interest and an important area of study [1–9]. The
brain has long been considered to be devoid of a conventional
lymphatic system. Studies in the last decade [1–3, 10–12]
have fundamentally altered the traditional model of cerebrospinal fluid (CSF) hydrodynamics and led to the conceptualization of a system responsible for the removal of interstitial
fluid (ISF) out of the brain, mostly from peri-venous pathways. This system has become known as the glymphatic
system [7, 10] and provides a pathway for an organized
convective fluid flow that drives clearance of interstitial
solute from the brain parenchyma. A large proportion of
subarachnoid CSF enters the interstitium through periarterial pathways and exchanges with ISF (CSF-ISF exchange), and both are cleared together with any associated
solutes along specific peri-venous pathways [1]. Because of
the unique anatomy of the brain parenchyma, biochemically inert waste such as MRI contrast agents can only be
removed through two possible pathways: a cerebrospinal
fluid (CSF) pathway and/or a vascular pathway. Although
controversy exists in the efflux pathways [1, 8, 13, 14],
there seems to be solid consensus about the participation
of the CSF pathway in CWC.
In addition to the CSF pathway, the vascular system can
play a role in helping with CWC. Invoking the vascular system as the major CWC pathway for non-specific substances
via the arachnoid granulations was published by Weed et al
over 100 years ago. Challenging this concept are novel insights utilizing molecular and cellular biology as well as
neuroimaging, which indicate that a direct transfer of molecules from the CSF to the venous system via arachnoid
granulations is up for debate [9, 15]. Several studies [9,
15–18] have clearly demonstrated that there is rapid transport of the macromolecules into the blood stream from the
brain parenchyma other than from the arachnoid granulations. However, these studies cannot identify the contribution of the vascular system in CWC. Consequently, a key

question about CWC remains controversial without solid
supportive data: whether non-specific waste with different
sizes can be directly removed by the brain parenchymal
vascular system. There are far more studies on how substances in the vascular system enter the brain, rather than on
how substances are removed from the brain via the vascular
pathway [19–21].
The major challenge in answering the question lies in the
need for an imaging tool that quantitatively measures tracer
influx and efflux in micro-vessels and their surroundings. In
order to address this critical need, we used superparamagnetic
iron oxide (SPIO)–enhanced susceptibility-weighted imaging (SWI, SPIO-SWI) to study this problem [22–25]. The
SPIO-SWI method capitalizes on the combination of the
SWI blooming effect (local signal loss from the presence
of magnetic field gradients) and the SPIO contrast agent’s
high susceptibility, in order to significantly increase the
detection sensitivity of sub-pixel micro-vessels. This
should provide the capability to distinguish between contributions from the peri-vascular versus intra-vascular
spaces. The objective of this study was to determine whether MRI tracers in the brain parenchyma can directly enter
the parenchymal vascular system following an
intracisternal magna (ICM) infusion.

Materials and methods
All experimental procedures were conducted and performed
in accordance with guidelines of the National Institute of
Health (NIH) for animal research under a protocol approved
by the Institutional Animal Care and Use Committees of
Wayne State University, and experimental guidelines of
ARRIVE (items 8, 10 to 13). All experimental procedures
were approved by the Institutional Animal Care Committee
of Wayne State University.

Experimental design
Figure 1a illustrates the logic behind the experimental
design in a simplified format: if tracers in the parenchymal arteries and tracers in the parenchymal veins can be
simultaneously measured, we can determine whether
there is tracer entering the parenchymal vascular system
from the parenchyma by comparing the amount of influx
tracers in arteries with efflux tracers in veins, even without knowing how tracers enter or exit the parenchymal
vascular system.

Animal studies
A total of 26 adult (3–4 months) male Wistar rats (350–450 g)
were used for the MRI studies (Fig. 1b). Five rats were used
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Fig. 1 a Illustration of the experimental design in a simplified format.
Regardless of how tracers enter or exit the brain parenchyma, a net
increase in the efflux tracers of the parenchymal vein compared to the
influx tracers of the parenchymal artery indicates that the tracers enter the

parenchymal vascular system. More specifically, there appears to be a net
increase in the veins but not in the arteries. b Experimental flowchart. c
Illustration of vessels of interest in 2D (left) and 3D (right)

to identify the artery and vein used in this study with IV
injection of Ferumoxytol at the optimized dosage of 5.6
mg/kg and to verify the experimental protocol (Fig. 2c).
One rat was used to confirm our previous optimized protocol for Fe-Dextran [9] and the capability of the SPIO-SWI
method to simultaneously distinguish parenchymal arteries,
veins, and corresponding para-vascular spaces (Fig. 2d–i).
A total of 20 rats were used to determine whether MRI
tracers in the brain parenchyma can directly enter the parenchymal vascular system with an ICM infusion of
Ferumoxytol or FeREX using different concentrations of
iron (Fig. 1b).

GmbH). Ferumoxytol is an iron replacement product used
clinically in the treatment of anemia; it is a nonstoichiometric magnetite (superparamagnetic iron oxide
(SPIO)) coated with polyglucose sorbitol carboxymethylether.
Its overall colloidal particle size is 17–31 nm in diameter.
FeREX™ is an SPIO having an iron core of approximately
5 nm. The size of the resulting colloidal matrix ranges from 50
to 150 nm. Fe-Dextran consists of cross-linked dextran iron
oxide composite particles with a size of 100 nm in diameter.
The original iron concentrations were 30 mg/mL in
Ferumoxytol, 10 mg/mL in FeREX™, and 2.4 mg/mL in
Fe-Dextran. Tracers were saline-diluted to achieve appropriate dosing. Tracers were either injected intravenously or ICM.

MRI experiments
Intra-cisterna magna infusion Unless intravenous administration was indicated, MRI tracers were administered via an ICM
infusion based on published studies documenting the optimized MRI infusion rate and a dosage to produce reliable
MRI data [26, 27]. Briefly, we had infused the CSF tracer at
an optimized rate of 1.67 μL/min for 54 min using a 100-μL
syringe (Hamilton Robotics), leading to a total infusion volume of about 90 μL CSF tracer.
MRI tracers All tracers were superparamagnetic iron oxide–
based: Ferumoxytol (Feraheme, AMAG Pharmaceuticals
I n c. ) , F e R E X ™ ( B i o P A L I n c. ) , an d F e - D e x t r a n
(nanomag®-CLD-redF, micromod-Partikeltechnologie

MRI measurements MRI measurements were performed with
a 7-T system (ClinScan; Bruker) on anesthetized rats laying
on a warming cradle with the temperature set to 38°C. The
dynamic tracer influx and clearance process was monitored
using a multi-echo 3D SWI scan [28]. For Ferumoxytol and
FeREX™ tracers, we used echo times of 5.22 ms, 12.97 ms,
and 20.71 ms; repetition time of 60 ms; flip angle of 15°; fieldof-view of 19 × 19 × 31 mm3 (read, phase, slice) in a coronal
orientation; matrix size of 384 × 192 × 192 (which yielded a
resolution of 50 × 100 × 160 μm3); and an acquisition time of
30 min. For the Fe-Dextran tracer, we used echo times of
2.69 ms and 7.71 ms; repetition time of 60 ms; flip angle of
15°; field-of-view of 16 × 16 × 28.16 mm3 in a coronal orientation; matrix size of 384 × 192 × 176 (which yielded an
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Fig. 2 MRI tracers injected into the CSF in rats are cleared into the
parenchymal veins. a, b Distinguishing cerebral arteries and veins on
SWI post-intravenous Ferumoxytol injection. a Baseline pre-injection:
azygos pericallosal artery (azp, red arrows) shows slight hyperintense
(bright) on SWI representing an inflow effect, but the azygos internal
cerebral vein (azicv, blue arrows) shows hypointense (dark) due to the
presence of deoxyhemoglobin. b 15 min post-injection: both artery and
vein show hypointense on SWI due to the iron-based contrast agent. c
Dynamic CSF tracer (240 μg (Fe) Ferumoxytol infusion via cisterna
magna) changes over time demonstrating early tracer influx (0–43 min)
followed by tracer clearance (43–100 min, white arrows indicate tracer
flow). d–i Distinguishing para-vascular vs intra-vascular spaces post-FeDextran CSF infusion for a representative rat. d, e Sagittal pre- and 1-h

post-ICM SPIO-SWIs (1st echo) of the azygos pericallosal artery (azp,
empty arrow) are bright (hyperintense) while para-arterial spaces (mustard arrows) are dark (hypointense). f azp cross-sectional signal intensity
profiles pre- and post-SPIO at 1-h time points (profile locations indicated
by red lines in d and e; black arrows: para-arterial space; empty arrow:
azp). g, h Sagittal pre- and 1-h post-ICM SPIO-SWIs (2nd echo) of the
azygos internal cerebral vein (azicv, empty arrows); mustard arrows:
para-venous spaces. i azicv cross-sectional signal intensity profiles preand post-SPIO at 1-h time points show temporal changes in the MR signal
intensities (profile locations indicated by red lines in g and h); empty
arrow: azicv; black arrows: para-venous spaces. CSF tracer entered in
the azicv but not azp via ICM infusion

original image resolution of 41.6 × 83.2 × 160 μm3); one
average; and an acquisition time of 30 min. The 30-min 3D
SWI sequence was continuously acquired for 2 h, that is, one
baseline scan followed by ICM infusion of the tracer and three
post-contrast scans. After 2 h, the 3D scan was repeated 2 to 3
times at a longer interval of 45 min with two other inserted
sequences (a coronal MR angiogram and a 3D T1-weighted
imaging) unrelated to this study. The post-contrast time was
determined from the beginning of the infusion to the middle of
each scan.

wayne.edu/). The quantitative susceptibility mapping (QSM)
was obtained similar to that presented in a previous publication [25]. The increase in the susceptibility is directly proportional to the amount of SPIO tracer present [28]. Arterialrelated parameters were measured using the first echo images
with better time-of-flight effects to highlight the arteries while
the venous system was evaluated using the second echo images which provide better susceptibility effects and hence better visualization of the veins. 3D regions-of-interest (ROIs)
were drawn manually on zoomed images (8 × in each direction in plane, zoom type: Fourier Windowed Sinc
Interpolated) for the azygos pericallosal artery (azp), azygos
internal cerebral vein (azicv), and corresponding para-

MRI data analysis MRI data were processed using in-house
software Signal Processing in NMR (SPIN) (http://www.mrc.
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vascular space. The MRI signal intensity (SI) was measured as
an average over all voxels in the 3D-ROIs (28 ± 7 slices for the
azp covering from the genu to the splenium of the corpus
callosum, 14 ± 3 slices for the azicv covering from the end
of the dorsal septal vein to the great cerebral vein of Galen).
The corresponding volume was measured from the product of
the number of voxels and a single voxel volume. Since the
number of slices was the same for pre- and post-images in a
given 3D-ROI, the ratio of the cross-sectional areas equals the
corresponding volume ratio. Vascular susceptibility values (in
parts per billion, ppb) were measured from the 3D-ROIs using
the above SI method from the QSM data. The venous pixels
were carefully selected to avoid touching the edges of the
neighboring very small para-venous spaces. Since the artery
had low susceptibility, it was measured at longer echo times
based on the 3D-ROIs obtained from the first echo magnitude
images. In order to reduce the effect of potential variations in
scale factor from scan to scan, the relative changes of the SI (in
percent) were used as follows: 100 × (SI(t)−SI(0))/SI(0),
where SI(0) refers to the SI at the pre-contrast time point,
and SI(t) to the post-contrast time points. The percentage
changes in signal were averaged over four post-contrast time
points (15, 45, 75, and 120 min) in the evaluation of the tracer
clearance rate between the azicv and its peri-venous space.

Statistical analysis
Data are presented as mean (± SE), while SI or susceptibility or their relative changes in percent are plotted as
bar and line graphs, as appropriate. Two-tailed, paired
sample t-tests were used to compare baseline to posttracer signal intensity measurements. Statistical significance was established at p values less than the critical
alpha value of 0.05. All statistics were performed using
Microsoft Excel.

Results
Visualization of arteries and veins using the SPIO-SWI
method
The SPIO-SWI method was able to distinguish parenchymal
arteries and veins in all 5 rats (Fig. 2a, b) under i.v. injection of
Ferumoxytol at a dose of 5.6 mg/kg. Dynamic tracer changes
using the SPIO-SWI method under ICM infusion of 240 μg
Fe for all 5 rats (Fig. 2c) were consistent with published CSF
pathways seen with other imaging methods [1, 5, 7, 9, 29].
The capability of simultaneously distinguishing the artery,
vein, and their corresponding para-vascular space is illustrated
in Fig. 2d–i under ICM infusion of Fe-Dextran at a quantity of
100 μg Fe.

CSF tracer entry into the parenchymal veins
Qualitative results We first qualitatively evaluated whether
the amount of MRI tracers in the brain parenchymal veins
was more than that in the brain parenchymal arteries
(Fig. 2d–i). Figure 2f clearly demonstrates that the MRI
tracers flowed along the para-arterial space but did not
enter the arterial blood: the intensity of the peak signal
from the azp remained virtually unchanged with time,
while the intensities of the two valleys (corresponding to
the azp para-arterial space) decreased. In contrast, Fig. 2i
shows that the MRI tracers flowed along the para-venous
space and entered the venous blood: the peak signal intensities from the venous blood of the azicv decreased with
time, indicating that the tracer in fact entered the azicv,
unlike the azp; similar to the para-arterial space in Fig. 2f,
the two dips in signal intensity (corresponding to the azicv
para-venous space) indicate that the tracers flowed along
the para-venous space. The mean (± SE) of the azp diameter was 0.15 (± 0.02) mm and the corresponding paravascular space was 0.06 (± 0.03) mm. The mean (± SE) of
the azicv diameter was 0.24 (± 0.02) mm and that of the
corresponding para-vascular space was less than 0.040
(± 0.003) mm.
Quantitative results using relative changes in MRI signal intensity We quantitatively measured CSF tracer in both the
azicv and azp using the SPIO-SWI method with 75 μg (Fe)
FeREX™ (100 nm) tracer, via ICM infusion. The relative
signal intensity changes (mean (± SE)%) in the venous ROI
(vROI) of the azicv decreased by 16.0 (± 4.1)% at 15 min
post-tracer infusion compared to baseline (pre-tracer)
(p < 0.01) (n = 5) (Fig. 3a). Similar findings were observed
with 270 μg (Fe): in this case, the signal decreased by 10.8
(± 2.5)% in the azicv (p = 0.02) (n = 5) (Fig. 3b). In contrast,
the relative changes (%) in signal intensity in the arterial
region-of-interest (aROI) of the azp were not significantly
different using the 75 μg (Fe) FeREX™ (100 nm) tracer, via
ICM infusion (p = 0.8) (n = 5) (Fig. 3a). However, we did
observe changes in the aROI when using the 270 μg (Fe)
(Fig. 3b); the relative decrease in SI in the aROI was 9.1
(± 2.8)% (p = 0.04) (n = 5) (Fig. 3b). Similar results were
obtained using a smaller MRI tracer, Ferumoxytol (17–31
nm) (n = 5) (Fig. 3c, d). The relative decrease in the SI for
the aROI of the azoxytol via ICM infusion (p = 0.051)
(n = 5) (Fig. 3c), which was larger than that of FeREX
although both of them were not significantly different from
zero.
Quantitative results using QSM data Susceptibility of the CSF
tracer was measured in both the azicv and azp. Figure 4a
shows that the CSF tracers entered the azicv with the 75 μg
(Fe) FeREX™ (100 nm) tracer via ICM infusion; the relative
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Fig. 3 Participation of the parenchymal venous pathway in CWC shown
by SWI post-SPIO CSF tracer infusion in normal rats. a, b Relative
changes (%) in MRI signal intensity pre/post 75 μg (Fe) (a) and 270 μg
(Fe) (b) FeREX™ (100 nm) in azygos pericallosal artery (azp) and azygos internal cerebral vein (azicv), demonstrating CSF tracer presence in
the azicv, but not the azp, with a low dose of iron. c, d Quantitative
relative changes (%) in MRI signal intensity pre/post 75μg (c) and
240 μg (d) Ferumoxytol in azp and azicv, demonstrating CSF tracer

presence in the azicv, but not in the azp, at a low dose of iron. e
Temporal MRI integral signals (mean ± SE) in the azicv and its corresponding para-venous space (pvs) for the 75 μg (Fe) FeREX (n = 5). The
estimated percent changes in the integral signal averaged over four time
points (2 h) was −18 (± 7)% for the vein and −57 (± 13)% for its corresponding para-vascular space. This gave an estimate of a ratio of 32:100
for FeREX percentage drainage from the vein and its corresponding PVS
without the consideration of the difference in their circulation speed

increase in susceptibility was 13.5 (± 1.0)% at 15 min posttracer infusion (p < 0.01) and 33.6 (± 6.7)% at 45 min posttracer infusion (p = 0.01), compared to baseline (pre-tracer)
(n = 5). In contrast to the parenchymal veins, negligible

amounts of CSF tracers entered the azp: 1.3 (± 2.6)% at
15 min post-tracer infusion (p = 0.6), and 12 (± 19)% at
45 min post-tracer infusion (p = 0.5), compared to baseline
(pre-tracer) (Fig. 4b).
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Fig. 4 Temporal relative changes in QSM with 75 μg (Fe) FeREX. QSM
relative changes (%) pre-, post-15min, and post-45min 75 μg (Fe)
FeREX™ (100 nm) CSF tracer in the azygos pericallosal artery (azp)
and the azygos internal cerebral vein (azicv), demonstrating CSF tracer
presence in the azicv, but not the azp at 75 μg (Fe). a An example rat mid-

sagittal QSM image for pre-, post-15 min, and post-45 min CSF tracer
showing a representative vein (azicv, arrows blue and upward) and artery
(azp, arrows red and downward). b Plot of the percent QSM change from
baseline over time for a select parenchymal artery (azp) and vein (azciv)
(n = 5)

Substantial contribution of the parenchymal venous
pathway to MRI tracer clearance

getting into the circulation blood pool is focused on the arachnoid villi [30–32]. However, this concept has been questioned
based on light microscopic examinations [9, 15, 18]. Our results provide an alternative explanation of this unanswered
question. Our study confirmed that the parenchymal venous
pathway can contribute substantially to CWC. The ratio of the
average percentage change in signals for the vein (azicv) versus the para-venous space was about 32:100. A value greater
than zero indicates the participation of the vein system in
CWC. This ratio would be further increased when considering
the differences in flow rate between the blood (2 mL/min) and
the CSF (3.7 μL/min) [33, 34]. That is, the brain parenchymal
venous system plays a substantial role in the clearance of
cerebral MRI tracers in addition to the CSF system (accounting for this flow ratio difference would change this ratio to
more than 10).
The ICM MRI tracers in the CSF can drain into the systemic blood circulation. Only the residual re-circulating
tracers remaining after the systemic removal by the liver,
spleen, and other waste clearance organs will be pumped back
into the blood and enter the arteries. At 240 or 270 μg (Fe)
tracer, we observed the CSF FeREX™ tracer in both the parenchymal arteries and veins, most likely indicating residual
systemic blood re-circulation of tracer, as opposed to direct
entry into the parenchymal arteries. An average adult rat
(~300 g) has a total blood volume about ~19 mL and a total
CSF volume of about ~0.58 mL (cisterna magna ~0.19 mL)
[35–37]. With a CSF tracer quantity of 75 μg eventually
draining into the systemic blood circulation (assuming complete drainage and without removal from the system), the concentration of tracer in the blood would be about ~3.95 μg/mL
(75 μg divided by 19 mL), about 3% of the initial CSF tracer
concentration. Considering tracer removal from the systemic
circulation by the reticuloendothelial system of the liver,
spleen, and bone marrow, the residual systemic tracer

We then determined whether the parenchymal venous pathway plays a substantial role in CWC as compared to the perivenous CSF pathway. Figure 3e shows the temporal changes
in the integral signal intensity of the azicv and its corresponding peri-venous space over a 2-h time period (n = 5, 18 slices
per rat) at the 75 μg (Fe) FeREX. The ratio of the average
percentage change in signal over four post-contrast time
points for the azicv versus the para-venous space was
32:100, without the consideration of the differences in the
rates of circulations of blood and CSF.

Discussion
Due, in part, to the lack of convincing evidence, most studies
on CWC do not discuss the possibility of the brain parenchymal vascular contribution, even though it has been recognized
that “if there is a transport mechanism for a substance at the
BBB, then the BBB is more important than peri-vascular pathways for the elimination of that substance,” because the circulation speed of the vascular system is more than one order
faster than that of CSF [21]. The SPIO-SWI method makes it
possible to simultaneously evaluate both influx and efflux
pathways of the parenchymal vascular system as well as the
CSF system with different sizes and concentrations of MRI
tracers. In this work, we have demonstrated quantitatively that
there is a net brain parenchyma-to-blood efflux of MRI tracers
into the venous system following ICM infusion of a tracer.
Other papers have reported that a large portion of the tracer
entering the blood stream from the CNS and only a relatively
small fraction of CSF tracer drain via the lymphatic channels
[9, 15–17]. The traditional explanation of the CSF tracer
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concentration would be less [38]. Therefore, the residual systemic re-circulation of the tracer can be ignored at 75 μg (Fe)
tracer quantity. However, at 270 μg (Fe) tracer quantity, the
residual tracer concentration in the blood is about 4-fold
higher, equivalent to a dose of 0.9 mg/kg (270 μg divided
by 300g); this corresponds to one-quarter of the typical IV
dose (4 mg/kg) used for T2*-weighted MRI scans, resulting
in significant signal intensity change within the parenchymal
arteries [25].
One might debate that the observation of the tracer entering
the parenchymal veins is due to the blooming effects (imaging
artifact) in the corresponding para-venous spaces. However,
this argument can be excluded by the observation that no
tracer was detected in or around the arteries when 75 μg
(Fe) tracer was used.
The finding that MRI tracers can enter the parenchymal
venous system but not the parenchymal arterial system is logically consistent with the well-known differences in the anatomical structures and functions between the venous and arterial systems. The observation of the venous removal of the
MRI tracers is consistent with the notion that tissue in the
human body drains about 90% of the interstitial fluid through
the venous system and the remaining 10% through the lymphatic system [39]. Considering the brain is the most bioactive, energy-consuming organ (20% nutrition for about 5% of
body weight) in the body [40], it is illogical that the brain
would rely on the slow CSF circulation for CWC while less
bioactive tissues outside the brain require both the fast vascular and slow lymphatic systems to remove waste in a timely
manner [19]. The size of the BBB is smaller than the USPIO
used here. The transcytosis can transport large substrates
across the BBB but the amount of USPIO detected in the
blood pool seems large than that from transcytosis. The mechanism behind this observation is unknown and warrants further investigation.
The direct participation of the parenchymal venous system
also questions our traditional understanding of the role of
arachnoid granulations in CWC. CSF involved with CWC
drains outside the brain parenchyma into the systemic blood
circulation via two routes, either directly through dural venous
sinuses via arachnoid granulations or indirectly through lymphatic pathways [41–43]. While there is a general consensus
on the two routes, the magnitude of each route’s involvement
was brought into question by previous studies [9, 15–18].
Welch et al reported that 5 h after the injection of albumin
dye into the CSF space of rabbits only 5% was seen draining
into the cervical lymph nodes [17]. This finding led to the
conclusion that only a small fraction of CSF drains via the
lymphatic channels. However, in the same period of time only
14% of the injected dye was found in the blood, revealing that
lymphatic channels contributed up to 26% of the tagged protein that had left the central nervous system and entered the
blood stream [16]. The CSF tracer entering blood stream is

most notable across the arachnoid villi/granulations [30–32].
However, their results were questioned since the dye was
injected at a pressure of up to 60 mmHg. High pressure during
the dye injection could cause rupture of the arachnoid villi/
granulations and absorption into the sinuses [31]. These studies have cast doubt on this understanding, inviting scientists to
rethink the exact role and magnitude of the arachnoid villi/
granulation route. Previously published work indicates that
the superior sagittal sinus was not a significant draining channel in normal and hydrocephalic rats, as evidenced by much
lower signal intensity changes on MRI in the superior sagittal
sinus versus the azygos internal cerebral vein, following lateral ventricle injection of tracer [9]. Logically, if waste in the
brain parenchyma can directly enter the parenchymal venous
system, and since blood circulation is much faster than the
CSF circulation, we can reasonably surmise that the arachnoid
granulations, which are located outside the brain parenchyma,
are at most, if at all, only a secondary pathway for CWC.
Beside the signal loss associated with the iron-based contrast agents, for low concentrations, we have also observed
positive signal enhancement in the vessels in the rat brain
using the SWI sequence at short echo times as would be expected from the T1 enhancing nature of these agents.
However, for higher concentrations this effect is overcome
by the large T2* relaxivity of the agents. Also, we should note
that the susceptibility results from QSM are independent of
signal magnitude.
This study has several limitations. First, it does not investigate all influx arterial vessels and all efflux venous vessels.
Second, it does not investigate the underlying mechanism for
how the MRI tracers enter the vascular system. Third, rats may
have different physiological waste clearance than humans.
The CWC in humans is much slower than that in rats and after
injection reaches a peak at ~10 h compared with ~ 2 h in rats
[5, 44]. Therefore, the whole CWC in humans needs to be
monitored over 1–2 days [45, 46]. We also do not consider
the waste clearance pathway or how waste drains or moves in
and out the brain to avoid possible confusion. We are designing experiments to address these issues in the future. Fourth,
we cannot exclude the possibility that prolonged anesthesia
could impact the physiological status of the animal and affect
the results. However, these effects on BBB permeability, if
any, are likely small and to-date there are no reports demonstrating significant changes of BBB permeability due to extended anesthesia. Fifth, a constant quantity of contrast agent
was used in the rats (body weights ranging from 350 to 450 g).
It would be better to use a constant dose in the future. Finally,
we used anisotropic spatial resolution in QSM due to imaging
time and signal-to-noise considerations. This should not affect
our results significantly since we use relative changes in susceptibility rather than absolute values.
In summary, using a state-of-art MR imaging technique
with iron-based contrast agents, we observed that not only
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MRI CSF tracers entered the parenchymal veins, but also the
parenchymal venous system contributed substantially to the
cerebral clearance of these tracers. These results challenge the
traditional understanding of the role of arachnoid granulations
in CWC. In conclusion, the parenchymal venous system appears to participate directly in CWC and complements the
established CSF pathways.
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